No Data
No Data
Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds
Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access Event
KANSAS CITY, Kan., June 25, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology
Express News | Cingulate Inc: Begun Nda Preparation and Expects to Submit Its Application in First Half of 2025
Express News | Cingulate Achieves Key Manufacturing Milestone in the Development of Its Adhd Drug Ctx-1301 in Preparation for FDA Marketing Clearance
Express News | FDA Clears Cingulate to File for Marketing Approval of Ctx-1301 in the Treatment of Adhd
10-Q: Quarterly report
No Data